Object: Spinal cord injury (SCI) is a devastating clinical syndrome for which no truly efficacious therapy has yet been identified. In preclinical studies, erythropoietin (EPO) and its nonerythropoietic derivatives asialoEPO and carbamylated EPO have markedly improved functional outcome when administered after compressive SCI. However, an optimum treatment paradigm is currently unknown. Because the uninjured spinal cord expresses a high density of EPO receptor (EPOR) in the basal state, signaling through these existing receptors in advance of injury (pharmacological preconditioning) might confer neuroprotection and therefore be potentially useful in situations of anticipated damage. Methods: The authors compared asialoEPO, a molecule that binds to the EPOR with high affinity but with a brief serum half-life (t_1/2 < 2 minutes), to EPO to determine whether a single dose (10 μg/kg of body weight) administered by intravenous injection 24 hours before 1 minute of spinal cord compression provides benefit as determined by a 6-week assessment of neurological outcome and by histopathological analysis. Rats pretreated with asialoEPO or EPO and then subjected to a compressive injury exhibited improved motor function over 42 days, compared with animals treated with saline solution. However, pretreatment efficacy was substantially poorer than efficacy of treatment initiated at the time of injury. Serum samples drawn immediately before compression confirmed that no detectable asialoEPO remained within the systemic circulation. Western blot and immunohistochemical analyses performed using uninjured spinal cord 24 hours after a dose of asialoEPO exhibited a marked increase in glial fibrillary acidic protein, suggesting a glial response to EPO administration. Conclusions: These results demonstrate that EPO and its analog do not need to be present at the time of injury to provide tissue protection and that tissue protection is markedly effective when either agent is administered immediately after injury. Furthermore, the findings suggest that asialoEPO is a useful reagent with which to study the dynamics of EPO-mediated neuroprotection. In addition, the findings support the concept of using a nonerythropoietic EPO derivative to provide tissue protection without activating the undesirable effects of EPO.

OBJECTIVE. The purpose of this study was to review the endoscopic anatomic features of the anterior brainstem and surrounding cisternal spaces via a tr

BACKGROUND: Antiapoptotis resulting from hyperactivation of the transcription factor NF‐κB has been described in several cancer types. It is triggered by the interaction of the tumor necrosis factor (TNF) with its receptors and recruitment of the intermediate factor TNF‐receptor associated factor (TRAF) 2. The NF‐κB transcriptional activity could amplify the expression of antiapoptotic genes. The authors investigated the activity of NF‐κB, and the mRNA expression of TNFα, TNFα receptor, TRAF1, TRAF2, and TRAF‐associated NF‐κB activator (TANK), and the antiapoptotic genes Bcl‐2, c‐IAP 1 and 2, and Survivin in human astrocytic tumors.METHODS: Eight low‐grade astrocytomas (LGA), 10 anaplastic astrocytomas (AAs), 10 glioblastoma multiforme (GBM) samples were used; 4 samples of normal brain tissue were used as controls. The NF‐κB activation was analyzed by electrophoretic mobility shift assay; TRAF1, TRAF2, TANK/I‐TRAF, Bcl‐2, c‐IAP 1 and 2, and Survivin mRNA expressions were studied using real‐time quantitative reverse‐transcriptase polymerase chain reaction.RESULTS: NF‐κB hyperactivity was detected in tumor samples. mRNA of antiapoptotic genes, particularly BCL‐2 and Survivin, was hyperexpressed in gliomas. Interestingly, BCL‐2 was hyperexpressed in LGAs, whereas a very high level of Survivin featured high‐grade gliomas. The differential expression of antiapoptotic genes yielded a tight clustering of all LGA and nearly all GBM samples in cluster analysis.CONCLUSIONS: NF‐κB and factors involved in its intracellular activation were up‐regulated in gliomas. NF‐κB‐activated antiapoptotic genes were hyperexpressed in tumor samples, but showed a differential expression with higher levels of Bcl‐2 in LGAs and higher levels of Survivin in GBMs. Cancer 2008. © 2008 American Cancer Society.

Intraoperative neurophysiological monitoring (IONM) is a crucial advancement in neurosurgery, enhancing procedural safety and precision. This technique involves continuous real-time assessment of neurophysiological signals, aiding surgeons in timely interventions to protect neural structures. In addition to inherent limitations, IONM necessitates a detailed anesthetic plan for accurate signal recording. Given the growing importance of IONM in neurosurgery, we conducted a narrative review including the most relevant studies about the modalities and their application in different fields of neurosurgery. In particular, this review provides insights for all physicians and healthcare professionals unfamiliar with IONM, elucidating commonly used techniques in neurosurgery. In particular, it discusses the roles of IONM in various neurosurgical settings such as tumoral brain resection, neurovascular surgery, epilepsy surgery, spinal surgery, and peripheral nerve surgery. Furthermore, it offers an overview of the anesthesiologic strategies and limitations of techniques essential for the effective implementation of IONM.

Single fraction radiosurgery is conventionally precluded for lesions lying <2-3 mm of the anterior visual pathway because of the radiosensitivity of the optic nerve. We analyzed a series of 64 patients with “perioptic” meningiomas treated by CyberKnife multisession radiosurgery and hypofractionated stereotactic radiotherapy (hSRT). Between July 2007-May 2010, patients were treated using conventional multisession Cyberknife schemes (2–5 fractions) and results were retrospectively analyzed. A radiobiological model was then developed to estimate the best tumor control probability (TCP)/ normal tissue complication probability (NTCP) for these lesions. Resulting dose/fraction schemes were applied to patients treated between May 2010 and July 2014. Data were prospectively collected Twenty-five patients were included in the retrospective part of the study. Median tumor volume was 4.95 cc; median dose was 23.0 Gy and median number of fraction was 5 (range 2–5). No patient had visual deterioration at mean follow-up of 60 ± 12 months. Tumor control was achieved in all cases. Thirty-nine patients were treated according the radiobiology model and results prospectively analyzed. Median tumor volume was 7.5 cc, median dose 25.0 Gy and mean number of fraction 5 (range 3–15). No patient had visual deterioration or tumor progression at mean follow-up of 17 ± 10 months. Conventional multisession CyberKnife treatments (2–5 fractions) provided satisfactory results. Nonetheless, our estimation of TCP suggests the use of higher doses to grant long-term disease control. To achieve higher equivalent doses without significantly increasing the NTCP, we suggest the use of a greater number of fractions, moving to hSRT, in tumors in which the encasement of optic nerves is presumed.